VideaHealth is a Boston-based dental technology company that combines the roles of an AI-powered diagnostic platform and a strategic partner to traditional dental suppliers. In essence, VideaHealth develops AI software to analyze dental radiographs (X-rays) and help dentists detect conditions like cavities, gum disease, and other oral pathologies in real time. At the same time, the company has aligned with major industry distributors – most notably Henry Schein, the world’s largest dental supply provider – to integrate its AI into widely used dental practice software and workflows. Through this dual approach, VideaHealth aims to standardize and enhance dental diagnostics across thousands of practices. Founded in 2018 as an MIT spinout by CEO Florian Hillen, the company launched its commercial platform in 2022 and has since positioned itself as a leading dental AI solution for large dental service organizations (DSOs) and clinics. VideaHealth’s mission is ultimately to improve patient outcomes by catching oral diseases earlier, enabling more preventive care and building patient trust in dental treatment recommendations.

Product

VideaHealth’s core product is the “VideaAI” platform, an FDA-cleared software suite that seamlessly integrates AI diagnostics into the dental workflow. The platform is composed of three main components – ClinicalAI, WorkflowAI, and EnterpriseAI – each addressing a different aspect of a dental practice’s needs:

• ClinicalAI (Chairside Diagnostics) – VideaHealth’s AI algorithms analyze intraoral and radiographic images (e.g. bitewing and periapical X-rays) to detect over 30 dental conditions, including tooth decay (caries), periapical lesions (abscesses), calculus (tartar), periodontal bone loss, and more. In January 2024, the company received FDA 510(k) clearance for its comprehensive AI system covering “30+ dental detections” – the broadest clearance in dental AI to date – including the first approval for an AI application in pediatric dentistry (for patients as young as 3). This means VideaAI can serve as a “second pair of eyes” across essentially all common findings on dental X-rays, highlighting areas of concern such as incipient cavities or early bone loss. The AI presents these findings as clear visual annotations on the radiograph, which helps dentists and hygienists see issues that might be subtle to the human eye. In an FDA trial, VideaHealth’s cavity-detection algorithm reduced dentists’ missed lesions by 43% and cut incorrect diagnoses by about 15%, demonstrating a significant improvement in diagnostic accuracy when AI is used as an assistive tool. All AI results are delivered chairside within seconds, allowing the clinical team to discuss them with the patient in real time.

  
  

• WorkflowAI (Practice Efficiency Tools) – Beyond detection, VideaHealth’s software automates parts of the clinical workflow and supports treatment planning. For example, it can automatically chart diagnosed conditions, suggest appropriate CDT codes, and even surface untreated conditions from past visits (to re-engage patients on needed care) in what Videa calls the “Videa Huddle” feature. By streamlining these tasks, WorkflowAI helps practices save time on documentation and ensures no potential production opportunities are overlooked. According to the company, the platform can save on the order of 1 hour per provider per day in administrative work, and increase average daily production by surfacing additional necessary treatments. VideaHealth reports that early adopter clinics have seen over $78,000 in annual production lift per practice (in restorative and periodontal treatments) and a 22% increase in case acceptance by patients, attributable to the AI’s ability to better communicate needs and prioritize care.

• EnterpriseAI (Analytics & Reporting) – A recent addition to the platform is VideaHealth’s analytics module, VideaInsights, which provides roll-up reporting and clinical performance dashboards for multi-location groups and DSOs. This allows organizational leaders to track key metrics such as diagnosis rates, treatment conversion, and consistency of care across their network. For instance, VideaInsights can identify if one location is under-diagnosing a certain condition relative to peers (highlighting a coaching opportunity) or estimate the value of untreated cases in each office. By benchmarking providers against AI-identified treatment opportunities, DSOs can target mentorship and measure improvements in care standardization. Early users have noted that such data visibility (which historically was limited to production numbers) helps reduce the need for in-person audits and improves clinical coaching effectiveness. In short, EnterpriseAI turns the millions of images analyzed by Videa into actionable business intelligence for dental practice management.

A key differentiator of VideaHealth’s product is its deep integration into existing dental software and workflows. The AI is designed to work with “90%+” of dental imaging systems and practice management software, and it is fully embedded in Henry Schein One’s Dentrix and Dentrix Ascend platforms. In fact, Dentrix (one of the most widely used practice management systems) was the first to natively integrate VideaHealth’s AI – launching it as “Dentrix Detect AI” in 2022 – so that clinicians can view AI results directly on X-rays inside the patient chart without importing/exporting images or using a separate application. When an X-ray is taken, the AI instantly analyzes it and overlays colored indicators for any cavities or bone level measurements, which the dentist or hygienist can toggle on and off during the exam. This tight integration means the technology “just runs in the background” of normal workflow: a practitioner can continue using their familiar imaging software, with the AI quietly flagging potential issues as a safety net. By eliminating extra steps, VideaHealth has aimed to drive high user adoption – and indeed reports 95%+ usage retention at 6 months among new users. The platform is delivered as a HIPAA-compliant cloud software (with ISO 13485 medical device quality certification), and Videa’s algorithms continuously learn from new data while being rigorously validated for safety and specificity to minimize false positives.

Another advantage VideaHealth emphasizes is the breadth and quality of data underpinning its AI models. The company built a proprietary dataset called the “Videa Factory,” comprising more than 100 million data points from dental X-rays and dental records aggregated via partnerships with DSOs, insurance companies, clearinghouses, and universities. This extensive training corpus (one of the largest in the dental AI field) has enabled Videa’s models to generalize across diverse patient populations and radiograph sources. According to CEO Florian Hillen, the AI has been trained on “50 times the number of X-rays that the average human dentist will see in a lifetime." This scale, combined with expert-annotated images (the company had 100+ dentists contribute to labeling pathology in millions of images), yields an AI that is highly sensitive to early disease. For example, Videa claims its caries detection can even spot decay beginning under existing fillings or in overlapping teeth where it might escape human eyes. Importantly, while the AI provides powerful analysis, it does not replace the dentist’s judgment – the software is marketed as a decision support tool. Dentists retain full control over diagnosis and treatment planning; the AI’s role is to ensure nothing is overlooked and to provide a visual aid that can improve dentist-patient communication. Many clinicians report that showing patients the AI-highlighted areas on an X-ray helps patients “see and believe” the diagnosis, resulting in greater trust and acceptance of recommended treatment. In summary, VideaHealth’s product differentiators include its comprehensive FDA-cleared diagnostic scope, robust accuracy backed by extensive data, and frictionless integration into the practice’s daily routine.

Team

VideaHealth was founded by Florian Hillen, who serves as CEO. Hillen’s background uniquely blends healthcare and technology: he earned dual master’s degrees in Computer Science and Technology Policy at MIT and also holds a medical degree and a business degree from institutions in Munich, Germany. Before starting VideaHealth, he conducted research at MIT’s Institute for Data, Systems and Society and at Harvard Business School, focusing on applications of AI in various medical domains. He also worked at McKinsey & Company as a consultant and had founded a prior digital health startup, experiences that gave him both the technical insight and operational savvy to launch VideaHealth. Hillen started the company in 2018 with initial seed funding from MIT (the MIT Sandbox and delta v accelerator provided an initial $50,000) and a vision to leverage AI for improving oral healthcare on a large scale. His guiding insight was that dentistry suffers from high variability and subjectivity in diagnoses – “10 different dentists could provide 10 different diagnoses to the same patient,” as he noted – and that AI could help standardize disease detection and enable earlier intervention.

In building out the team, VideaHealth has attracted talent with deep experience in both dentistry and software. The company’s leadership includes Dan Bachiochi (VP of Engineering), formerly of robotics firm iRobot, Joe Cuccinelli (VP of Product), and Adam Foresman (Director of Regulatory Affairs) who helped steer the FDA clearance process. The mix of technical AI experts, clinical advisors (including practicing dentists on its clinical advisory board), and dental industry veterans reflects VideaHealth’s need to navigate both AI development and the practical realities of dental practice operations. The team is on a mission “to help dental practices deliver better care to 1 billion patients globally with AI".

Traction and Adoption

Since its commercial launch in 2022, VideaHealth has shown strong uptake, especially among enterprise clients. As of early 2025, the company reports that its AI platform is used by over 50,000 dental clinicians across 50+ DSOs and large groups, and that it is now analyzing more than 500 million dental X-rays annually on their behalf. This scale-up has been rapid – by mid-2023, Videa had around 30,000 users, indicating nearly a doubling of users in under two years as additional DSO rollouts and Dentrix sign-ups kicked in. Importantly, user engagement appears high: VideaHealth cites a >95% monthly active usage rate among installed providers, suggesting that once a practice enables the AI, it becomes a routine part of daily care (this contrasts with some healthtech tools that end up underutilized). In feedback from clients, dentists often highlight improvements in case acceptance and patient communication. For example, Gen4 Dental Partners (a DSO) noted that using Videa’s “Patient View” visualization tools alongside AI detections allowed them to schedule treatments more promptly and reduce patient complications from delayed care. Financially, practices have seen tangible returns: one metric collected across certain beta sites was an average of $100,000 in additional identified treatment opportunities per practice per month that the AI surfaced (e.g. catching restorative needs that might otherwise be missed). These outcomes are heavily featured in VideaHealth’s case studies and sales materials, as they speak directly to a dentist’s dual priorities of patient health and practice revenue.

Market

VideaHealth operates in the emerging market of dental AI and diagnostics software. Dentistry as a field is undergoing a digital transformation – over the past two decades, most offices have migrated from film to digital X-rays and from paper charts to electronic dental records, setting the stage for advanced software like AI to be layered on top.

Several factors are driving growth in dental AI adoption. First, there is a clinical need for greater accuracy and consistency in diagnosis. Studies have shown that dentistry has one of the highest rates of missed disease among medical fields – diagnoses can vary widely between practitioners, and subtle problems often go unnoticed until they become advanced. AI promises to reduce that variability by acting as an objective second opinion on every exam. Early deployments (like VideaHealth’s trials) have demonstrated that AI can indeed uncover a significant number of additional carious lesions or incipient problems that humans miss. Catching these issues earlier not only improves patient outcomes (less invasive treatment needed) but also increases production for practices, a win-win that makes the value proposition of AI quite compelling.

Second, patient expectations and the patient experience are influencing the market. Modern dental patients are more tech-savvy and often appreciate visuals and high-tech touches in their care; seeing an AI analysis can build trust that the dentist is thorough and using the latest tools. There’s evidence that AI tools can boost patient case acceptance rates (by ~20–30%) because patients better understand the diagnosis and feel a computer-validated finding is more concrete.

Third, regulatory and insurance trends are moving in favor of dental AI. The U.S. FDA has been increasingly receptive, clearing multiple dental AI algorithms over 2022–2023, which provides confidence to providers that these tools are safe and effective. Insurance companies are also starting to consider reimbursing certain uses of AI or using AI themselves – for example, some carriers have begun pilot programs where a “clean” AI evaluation of an X-ray could streamline claims approval for a procedure. This broader ecosystem support lowers barriers to adoption.

Competition

VideaHealth’s primary direct competitors are Overjet and Pearl, two other venture-backed companies focused on AI for dental imaging, and it also faces competition (or potential partnership threats) from large dental equipment manufacturers integrating AI into their products.

• Overjet: Founded in 2018 and based in Boston like Videa. Overjet’s AI software similarly analyzes dental X-rays for conditions such as cavities and periodontal bone loss. The company distinguished itself early by targeting not only dental practices but also dental insurance payers – Overjet secured contracts with major insurers (like Delta Dental) to help automate claims review and fraud detection. On the clinical side, Overjet has FDA clearances for its “Dental Assist” AI platform, including capabilities to detect caries and to quantify bone level measurements on X-rays. By mid-2023, Overjet had obtained its fourth FDA clearance, which expanded use of its AI to younger patients (pediatric clearance). Overjet has been aggressive in deployment: for example, it partnered with Dental Care Alliance (one of the largest DSOs with 400+ practices) for a full-network AI rollout. In terms of funding, Overjet has raised more capital than Videa or Pearl – it closed a $42.5 million Series B in late 2021 (at a $425M valuation) and a $53 million Series C in 2022, which at the time was the largest single investment in dental AI on record. Overjet’s go-to-market overlaps with VideaHealth in DSOs, but Overjet’s strong insurance focus gives it a somewhat different angle. From a product standpoint, Overjet emphasizes its precise measurements (e.g., quantifying bone loss in millimeters) and claims 100% of dentists in studies detected caries more accurately with its tool. A key competitive consideration is distribution: Overjet does not have an equivalent to the Dentrix partnership; instead, it offers integrations with various imaging software. VideaHealth and Overjet often find themselves compared feature-for-feature in DSO evaluations, and both are racing to improve AI capabilities (Overjet also secured a patent for image enhancement AI and is exploring 3D imaging analysis).

• Pearl: Los Angeles-based Pearl is another leading startup in this space. Pearl achieved notoriety by securing the first FDA clearance (in March 2022) for AI that can assist in detecting multiple dental pathologies on X-rays. That product can identify common conditions like cavities, calculus, root abscesses, and crown margins – initially for adult teeth, and later expanded to patients as young as 12. Pearl has been very globally focused: before FDA approval, it obtained CE Mark clearance in Europe and rolled out Second Opinion in over 80 countries. In 2023, Pearl announced a partnership with Planmeca, a major dental equipment manufacturer, to integrate Pearl’s AI directly into Planmeca’s Romexis imaging software used by thousands of offices worldwide. This integration with a hardware vendor is somewhat analogous to Videa’s Dentrix software partnership, and it gives Pearl a strong distribution channel internationally (Planmeca is a Finnish company with global dental market presence). Pearl has also partnered with practice management systems like Curve Dental and Carestack to embed its AI into their workflows. In terms of funding, Pearl has raised significant capital as well – in mid-2024 Pearl closed a $58 million Series B led by Left Lane Capital. Pearl’s value proposition centers on being an objective “second opinion” for dentists and patients – in fact, it markets Second Opinion for patient-facing use, including a consumer-oriented app in some regions. Competitively, Pearl and VideaHealth have a lot of overlap: both offer broad condition detection, both have a strong U.S. DSO focus now, and both are working on analytics (Pearl has a product “Practice Intelligence” for analytics). Pearl’s advantages include a head-start in Europe and a large annotated data set (it has processed millions of X-rays from around the world, giving it a diverse training base).

• Imaging & Software Incumbents: In addition to the AI-focused startups, VideaHealth faces competition or potential disruption from large dental product companies who are developing their own AI solutions or partnering to do so. For example, Envista Holdings has introduced AI features in its imaging software. In 2023, DEXIS earned FDA clearance for its DTX Studio Clinic software’s AI module, which can analyze x-rays for pathology as part of an integrated imaging suite. This was notable because it marked one of the first times an established dental manufacturer obtained an AI clearance, signaling that incumbents are not going to cede the market entirely to startups. DEXIS’s solution can automatically highlight caries and other anomalies on x-rays taken with DEXIS sensors, offering similar benefits (consistency, patient visualization) within a closed ecosystem. Likewise, Planmeca’s partnership with Pearl (as mentioned) effectively means Planmeca is an AI competitor, choosing to embed Pearl’s tech into their offering rather than build from scratch. Other competitors in the traditional camp include Carestream Dental, which has previewed AI tools in its imaging software, and Dentsply Sirona, which has been investing in digital dentistry. It’s also worth noting that third-party dental software providers can partner with AI startups or develop basic AI themselves. For instance, Amazon Web Services launched some generic medical imaging AI services that could theoretically be trained for dental use, available to any software vendor.

From VideaHealth’s perspective, the presence of these big players means two things: (1) Partnership opportunities – as seen with Henry Schein One choosing Videa’s tech, an incumbent may decide it’s better to partner or invest in a startup’s solution rather than build their own. VideaHealth’s strategy to secure the Dentrix integration was a competitive win in this regard, as it pre-empted a rival (like Overjet or Pearl) from occupying that channel. And (2) eventual consolidation or head-to-head competition – if companies like Envista or Dentsply decide to heavily push their own AI, VideaHealth will need to stay ahead in accuracy and features to maintain an edge. The fact that DEXIS obtained FDA clearance in 2023 for AI imaging shows that big manufacturers can and will validate their technology when ready. However, one advantage for the startups is that dental practitioners often use a mix of equipment and software, so an “agnostic” AI that works on all images (like Videa, Pearl, Overjet) can be more attractive to a DSO than a piecemeal solution tied to one brand of X-ray sensor.

Financials & Fundraising

VideaHealth, a privately held venture-backed company, has successfully raised approximately $70 million as of early 2025, reflecting growing investor confidence in its dental AI technology and market traction. Its journey began with

• 2018–2020 (Seed Funding): $6.5 million in seed funding from Pillar VC, Zetta Venture Partners, and the MIT ecosystem, which supported initial AI development and pilot studies.

• March 2022 (Series A): A significant milestone was the $20 million Series A led by Spark Capital. This round, secured just before VideaHealth obtained crucial FDA clearance, was aimed at expanding its diagnostic capabilities and forging key partnerships, notably with Dentrix.

• January 2025 (Series B): Following rapid growth and achieving tens of thousands of users, VideaHealth raised a $40 million Series B led by Threshold Ventures with participation from all major existing investors. This capital is fueling further platform scaling, R&D, and market expansion.

• 
  

While detailed financials are private, the company's significant user base suggests multi-million dollar annual recurring revenue and a high-growth trajectory, achieved with notable capital efficiency. VideaHealth's investors bring strategic expertise, and its fundraising path showcases a classic high-growth health tech trajectory: proving the technology, demonstrating market demand, and then scaling aggressively.

The Future

As VideaHealth looks ahead, its prospects will be shaped by both its internal execution and the broader adoption curve of AI in dentistry. In the near term (next 2–3 years), the company’s focus is on deepening penetration in the dental industry – converting early enthusiasm for AI into a lasting standard of care. This likely means expanding its user base from tens of thousands of clinicians to hundreds of thousands. Given that the U.S. alone has around 200,000 practicing dentists, there is a large addressable market still untapped. VideaHealth will continue targeting DSOs (several large groups remain that haven’t yet adopted an AI solution) as well as rolling out to more independent practices via the Dentrix integration. We can expect VideaHealth to enter new geographic markets, likely starting with Europe (where it already has EU MDR approval) and perhaps parts of Asia via partnerships. Its competitor Pearl has been active internationally; VideaHealth may follow suit by teaming up with global distributors or imaging companies to offer its platform abroad.

One trend that bodes well for VideaHealth’s future is the accelerating acceptance of AI by dental professionals. Initially, some dentists were skeptical or concerned that AI might undermine their expertise, but as more success stories emerge, the attitude is shifting. Industry thought leaders predict that in a few years AI will be as commonplace in dentistry as digital x-rays are today. Some dental schools are also incorporating AI into curricula, which means the next generation of dentists will enter the field expecting to use such tools. VideaHealth, by engaging with educational institutions. Over the next decade, one can imagine regulatory bodies or standard-of-care guidelines evolving to encourage AI use – perhaps insurers might require an AI screening on radiographs for certain claims, or malpractice insurers could give discounts to AI-equipped offices as a risk mitigation. These developments would further drive adoption and benefit companies like VideaHealth that are leading the space.

 In summary, the future for VideaHealth is promising but will require navigating a rapidly evolving landscape. The company stands at the forefront of a technological shift in dentistry, with a head start in DSO deployment and a robust platform. If it can maintain technical superiority, expand wisely (both geographically and into adjacent products), and perhaps even partner or merge strategically, VideaHealth could become the de facto AI infrastructure in dental care worldwide.

Sources

• VideaHealth press release, Business Wire (Mar 31, 2022): “VideaHealth Raises $20 Million to Expand AI in the Dentist’s Chair for Millions of Patients”businesswire.combusinesswire.com

• Fierce Biotech (May 3, 2022): “FDA plays tooth fairy, awards clearance to VideaHealth’s cavity-spotting AI”fiercebiotech.comfiercebiotech.com

• VideaHealth About Us – Message from CEO Florian Hillen (2024)videa.aividea.ai

• VideaHealth Blog (Jan 4, 2024): “VideaHealth achieves landmark FDA clearance for 30+ dental conditions”videa.aividea.ai

• Dentrix (Henry Schein One) official page: “Dentrix Detect AI – powered by VideaHealth”dentrix.com

• Dental Product Shopper Magazine (2023): “Dentrix and Dentrix Ascend Detect AI: AI for Next-Level Patient Care”dentalproductshopper.comdentalproductshopper.com

• Becker’s Dental Review (Oct 20, 2022): “Dental tech veteran joins VideaHealth as VP of Business Development”beckersdental.combeckersdental.com

• Becker’s Dental Review (Jan 28, 2025): “VideaHealth secures $40M investment”beckersdental.com

• Business Wire press release (Jan 28, 2025): “VideaHealth Raises $40M in Series B Funding to Revolutionize Dental Care with AI”videa.aividea.ai

• SiliconANGLE (Jan 28, 2025): “AI dentistry startup VideaHealth bites off $40M in funding”siliconangle.comsiliconangle.com

• TechCrunch (Jul 24, 2024): “Pearl raises $58M to help dentists make better diagnoses using AI”techcrunch.comtechcrunch.com

• Becker’s Dental Review (Jul 18, 2023): “4 dental AI companies earning FDA clearance, patents in 2023”beckersdental.combeckersdental.com

• Planmeca press via Becker’s (Apr 19, 2023): “Planmeca to integrate Pearl’s dental AI technology”beckersdental.com

• Grand View Research (2024): “Digital Dentistry Market Size & Trends” (market size data)grandviewresearch.com

• Credence Research (May 8, 2025): “Dental Digital Treatment Software Market, 2024–2032”credenceresearch.comcredenceresearch.com

• Pulse 2.0 Interview (Jul 5, 2023): “VideaHealth: AI helps dental clinicians detect signs of oral disease”pulse2.compulse2.com

• Heartland Dental News (2023 via Epicos): Heartland’s partnership giving 20k providers access to VideaAIepicos.com

• Dentistry Today (Sept 29, 2022): coverage of VideaHealth’s $20M Series A and impactbusinesswire.combusinesswire.com

• (Additional citations within text from VideaHealth website, press releases, and industry news as labeled above)